Goldman Reduces Bausch & Lomb to 'In-Line'

Analyst Lawrence Keusch says the eye-care company's share price has reached its fair value

Goldman Sachs downgraded Bausch & Lomb (BOL ) to in-line from outperform.

Analyst Lawrence Keusch says although he still expects cost cutting to remain on track, shares now trade within 1% of the estimated $40 fair value as determined by a 10-year discounted cash flow analysis. He says shares now are meaningfully ahead of the medical device group's average of 14%.

However, Keusch still expects Bausch & Lomb to meet or exceed the $2.08 2003 earnings per share estimate, based on operational outperformance and the benefits of foreign-exchange rates. Nonetheless, with few near-term catalysts, and with the stock having reached its estimated fair value, Keusch says he now expects the shares to perform in line with his covered universe.

Before it's here, it's on the Bloomberg Terminal.